Polpharma Biologics

Biosimilar antibodies · Immunology, ophthalmology, MS

Overview

One of Europe's larger biosimilar developers/manufacturers (tocilizumab, ranibizumab, natalizumab). Out-licenses to global players from its large Duchnice biotech campus.

What they do

Polpharma Biologics is one of Europe's larger biosimilar monoclonal antibody developers and manufacturers, operating an integrated biotech campus in Duchnice, Poland, alongside additional R&D sites. Part of the wider Polpharma group, it spans cell-line development, process development and large-scale GMP biomanufacturing, and typically out-licenses its products to global commercialization partners rather than selling them directly.

Lead program & status

Its portfolio targets immunology, ophthalmology and multiple sclerosis. Notable assets include a ranibizumab biosimilar developed through Bioeq (its joint venture with Formycon), which reached the US market as CIMERLI (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis. Its natalizumab biosimilar (PB006/PB016) has been partnered with Sandoz for global commercialization and in-licensed by Fresenius Kabi, with regulatory filings accepted by the FDA and EMA. The company has continued signing licensing deals into 2024-2026, including partnering arrangements extending its autoimmune biosimilars into additional regions such as Latin America. It also develops a tocilizumab biosimilar within its pipeline.

Why it matters

Polpharma Biologics shows Poland competing in capital-intensive biomanufacturing at scale, supplying global partners with biosimilars in major therapeutic areas and lowering the cost of access to complex biologic medicines.

FAQ

Does Polpharma Biologics sell drugs directly?

Generally no. It develops and manufactures biosimilars and out-licenses them to global commercialization partners such as Sandoz, Fresenius Kabi and, via the Bioeq JV, Coherus.

What is its most notable approved product?

Its ranibizumab biosimilar, developed through the Bioeq JV, reached the US market as CIMERLI (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis.

Where does Polpharma Biologics manufacture?

It operates a large integrated biotech campus in Duchnice, Poland, covering development through large-scale GMP biomanufacturing.

Company website / source ↗ Open the interactive map →